Related Experiment Video
Updated: Apr 7, 2026
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
A Doubly Caged Bis(salicylamide)-Based Anion Transporter for Phototriggered Breast Cancer Therapy
Naveen J Roy1, Ronedy Naorem1, Benchamin Abraham2
1Chemistry Department, Indian Institute of Science Education and Research Pune, Pune, Maharashtra 411008, India.
Abstract:
Formulation of ion transporters, which hold great potential for anticancer therapy, as prodrugs/protransporters can overcome their nontarget activity, allowing for local activation using specified stimuli. Photocleavable protecting groups offer a robust strategy for caging transporter activity. Their reliance on light as a stimulus ensures ease of application and precise spatiotemporal control. Thus, there is a need to develop protransporters that are activatable in the biologically benign visible region of the electromagnetic spectrum. Herein, we report a series of bis-(salicylamide)-based anion antiporters caged with o-nitrobenzyl groups to create protransporters that can be activated by 405 nm light. Active transporter release via two-step photocleavage and the subsequent photoinduced recovery of ion transport activity was verified. In vitro photoactivation of protransporters using 405 nm light efficiently induced cell death in MCF-7 and triple-negative MDA-MB-231 breast cancer cell lines.
Insights
Researchers developed novel photocleavable anion antiporter protransporters. Activated by visible light (405 nm), these prodrugs enable targeted anticancer therapy, demonstrating efficacy in breast cancer cell lines.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Cancer Therapeutics
Background:
- Ion transporters are promising anticancer agents but suffer from off-target effects.
- Prodrug strategies, particularly photocleavable protecting groups, offer localized activation.
- Visible light activation is desirable for safe and precise therapeutic control.
Purpose of the Study:
- To design and synthesize novel protransporters based on bis-(salicylamide)-based anion antiporters.
- To develop protransporters activatable by visible light (405 nm) for targeted cancer therapy.
- To validate the photocleavage mechanism and in vitro efficacy of the developed protransporters.
Main Methods:
- Synthesis of bis-(salicylamide)-based anion antiporters caged with o-nitrobenzyl groups.
- Photocleavage studies using 405 nm light to release active transporters.
- In vitro cell-based assays using MCF-7 and MDA-MB-231 breast cancer cell lines.
Main Results:
- Successful synthesis of protransporters activated by 405 nm light.
- Demonstration of a two-step photocleavage mechanism leading to active transporter release.
- Significant induction of cell death in breast cancer cell lines upon photoactivation.
Conclusions:
- Bis-(salicylamide)-based anion antiporter protransporters can be effectively activated by visible light.
- This approach offers a spatiotemporally controlled method for targeted anticancer drug delivery.
- The developed protransporters show potential for treating breast cancer, including triple-negative subtypes.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
